Sylvia K Plevritis

List of Publications by Year
in descending order

116 papers	16,211 citations	46984 47 h-index	25770 108 g-index
118 all docs	118 docs citations	118 times ranked	24972 citing authors

#	Article	IF	Citations
1	The prognostic landscape of genes and infiltrating immune cells across human cancers. Nature Medicine, 2015, 21, 938-945.	15.2	2,505
2	Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer. New England Journal of Medicine, 2005, 353, 1784-1792.	13.9	2,169
3	Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum. Science, 2011, 332, 687-696.	6.0	2,097
4	Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE. Nature Biotechnology, 2011, 29, 886-891.	9.4	905
5	Effects of Mammography Screening Under Different Screening Schedules: Model Estimates of Potential Benefits and Harms. Annals of Internal Medicine, 2009, 151, 738.	2.0	509
6	Non–Small Cell Lung Cancer: Identifying Prognostic Imaging Biomarkers by Leveraging Public Gene Expression Microarray Data—Methods and Preliminary Results. Radiology, 2012, 264, 387-396.	3.6	384
7	Benefits and Harms of Computed Tomography Lung Cancer Screening Strategies: A Comparative Modeling Study for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 2014, 160, 311.	2.0	377
8	Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. Nature Medicine, 2014, 20, 769-777.	15.2	349
9	Association of a Leukemic Stem Cell Gene Expression Signature With Clinical Outcomes in Acute Myeloid Leukemia. JAMA - Journal of the American Medical Association, 2010, 304, 2706.	3.8	339
10	Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1116-25.	3.3	307
11	Intestinal Enteroendocrine Lineage Cells Possess Homeostatic and Injury-Inducible Stem Cell Activity. Cell Stem Cell, 2017, 21, 78-90.e6.	5.2	280
12	Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood, 2013, 121, 1604-1611.	0.6	279
13	Glioblastoma Multiforme: Exploratory Radiogenomic Analysis by Using Quantitative Image Features. Radiology, 2014, 273, 168-174.	3.6	265
14	Ly6d marks the earliest stage of B-cell specification and identifies the branchpoint between B-cell and T-cell development. Genes and Development, 2009, 23, 2376-2381.	2.7	254
15	Cost-effectiveness of Screening BRCA1/2 Mutation Carriers With Breast Magnetic Resonance Imaging. JAMA - Journal of the American Medical Association, 2006, 295, 2374.	3.8	240
16	Survival Analysis of Cancer Risk Reduction Strategies for *BRCA1/2* Mutation Carriers. Journal of Clinical Oncology, 2010, 28, 222-231.	0.8	217
17	Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study. PLoS Medicine, 2017, 14, e1002277.	3.9	216
18	Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies. Annals of Internal Medicine, 2016, 164, 215.	2.0	209

#	Article	IF	Citations
19	Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012. JAMA - Journal of the American Medical Association, 2018, 319, 154.	3.8	209
20	Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review. JNCI Cancer Spectrum, 2018, 2, pky062.	1.4	199
21	Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography. JAMA - Journal of the American Medical Association, 2021, 325, 988.	3.8	181
22	A radiogenomic dataset of non-small cell lung cancer. Scientific Data, 2018, 5, 180202.	2.4	167
23	Extracting binary signals from microarray time-course data. Nucleic Acids Research, 2007, 35, 3705-3712.	6.5	145
24	Non–Small Cell Lung Cancer Radiogenomics Map Identifies Relationships between Molecular and Imaging Phenotypes with Prognostic Implications. Radiology, 2018, 286, 307-315.	3.6	140
25	Risk-Based lung cancer screening: A systematic review. Lung Cancer, 2020, 147, 154-186.	0.9	136
26	Predictive radiogenomics modeling of EGFR mutation status in lung cancer. Scientific Reports, 2017, 7, 41674.	1.6	124
27	Effects of Screening and Systemic Adjuvant Therapy on ER-Specific US Breast Cancer Mortality. Journal of the National Cancer Institute, 2014, 106, .	3.0	120
28	The effect of age, race, tumor size, tumor grade, and disease stage on invasive ductal breast cancer survival in the U.S. SEER database. Breast Cancer Research and Treatment, 2005, 89, 47-54.	1.1	118
29	Pancancer analysis of DNA methylation-driven genes using MethylMix. Genome Biology, 2015, 16, 17.	3.8	117
30	Prognostic PET 18F-FDG Uptake Imaging Features Are Associated with Major Oncogenomic Alterations in Patients with Resected Non–Small Cell Lung Cancer. Cancer Research, 2012, 72, 3725-3734.	0.4	111
31	Lymph node colonization induces tumor-immune tolerance to promote distant metastasis. Cell, 2022, 185, 1924-1942.e23.	13.5	111
32	Visualization and cellular hierarchy inference of single-cell data using SPADE. Nature Protocols, 2016, 11, 1264-1279.	5.5	99
33	Cross-Species Functional Analysis of Cancer-Associated Fibroblasts Identifies a Critical Role for CLCF1 and IL-6 in Non–Small Cell Lung Cancer <i>In Vivo</i>. Cancer Research, 2012, 72, 5744-5756.	0.4	96
34	Risk Stratification for Second Primary Lung Cancer. Journal of Clinical Oncology, 2017, 35, 2893-2899.	0.8	92
35	Genomic and Proteomic Analysis Reveals a Threshold Level of MYC Required for Tumor Maintenance. Cancer Research, 2008, 68, 5132-5142.	0.4	87
36	Online Tool to Guide Decisions for<i>BRCA1/2</i>Mutation Carriers. Journal of Clinical Oncology, 2012, 30, 497-506.	0.8	81

#	Article	IF	Citations
37	Cost-Effectiveness Analysis of Lung Cancer Screening in the United States. Annals of Internal Medicine, 2019, 171, 796.	2.0	81
38	Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma. Cancer, 2004, 100, 479-489.	2.0	77
39	*GFPT2*-Expressing Cancer-Associated Fibroblasts Mediate Metabolic Reprogramming in Human Lung Adenocarcinoma. Cancer Research, 2018, 78, 3445-3457.	0.4	75
40	Multi-omic single-cell snapshots reveal multiple independent trajectories to drug tolerance in a melanoma cell line. Nature Communications, 2020, 11, 2345.	5.8	74
41	Incidental Extracardiac Findings at Coronary CT: Clinical and Economic Impact. American Journal of Roentgenology, 2010, 194, 1531-1538.	1.0	73
42	A Comparative Modeling Analysis of Risk-Based Lung Cancer Screening Strategies. Journal of the National Cancer Institute, 2020, 112, 466-479.	3.0	67
43	Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials. Cancer, 2014, 120, 1713-1724.	2.0	65
44	Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non–Small Cell Lung Cancer. Journal of the National Cancer Institute, 2015, 107, djv211.	3.0	64
45	MiDReG: A method of mining developmentally regulated genes using Boolean implications. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 5732-5737.	3.3	57
46	A natural history model of stage progression applied to breast cancer. Statistics in Medicine, 2007, 26, 581-595.	0.8	54
47	Fast calculation of pairwise mutual information for gene regulatory network reconstruction. Computer Methods and Programs in Biomedicine, 2009, 94, 177-180.	2.6	52
48	NF-ÎºB protein expression associates with 18F-FDG PET tumor uptake in non-small cell lung cancer: A radiogenomics validation study to understand tumor metabolism. Lung Cancer, 2014, 83, 189-196.	0.9	51
49	Identification of ovarian cancer driver genes by using module network integration of multi-omics data. Interface Focus, 2013, 3, 20130013.	1.5	50
50	Disparities of National Lung Cancer Screening Guidelines in the US Population. Journal of the National Cancer Institute, 2020, 112, 1136-1142.	3.0	48
51	Chapter 12: A Stochastic Simulation Model of U.S. Breast Cancer Mortality Trends From 1975 to 2000. Journal of the National Cancer Institute Monographs, 2006, 2006, 86-95.	0.9	45
52	Effect of Screening and Adjuvant Therapy on Mortality From Breast Cancer. Obstetrical and Gynecological Survey, 2006, 61, 179-180.	0.2	44
53	A Simulation Model to Predict the Impact of Prophylactic Surgery and Screening on the Life Expectancy of *BRCA1* and *BRCA2* Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1066-1077.	1.1	43
54	Discovering Biological Progression Underlying Microarray Samples. PLoS Computational Biology, 2011, 7, e1001123.	1.5	42

#	Article	IF	Citations
55	DRUG-NEM: Optimizing drug combinations using single-cell perturbation response to account for intratumoral heterogeneity. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E4294-E4303.	3.3	42
56	Identification of cell types in multiplexed in situ images by combining protein expression and spatial information using CELESTA. Nature Methods, 2022, 19, 759-769.	9.0	42
57	Magnetic Resonance Imaging Characteristics of Fibrocystic Change of the Breast. Investigative Radiology, 2005, 40, 436-441.	3.5	38
58	Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 17432-17437.	3.3	38
59	Comparing Benefits from Many Possible Computed Tomography Lung Cancer Screening Programs: Extrapolating from the National Lung Screening Trial Using Comparative Modeling. PLoS ONE, 2014, 9, e99978.	1.1	38
60	Evaluating the impact of varied compliance to lung cancer screening recommendations using a microsimulation model. Cancer Causes and Control, 2017, 28, 947-958.	0.8	38
61	A Simulation Model Investigating the Impact of Tumor Volume Doubling Time and Mammographic Tumor Detectability on Screening Outcomes in Women Aged 40â€"49 Years. Journal of the National Cancer Institute, 2010, 102, 1263-1271.	3.0	37
62	Common Model Inputs Used in CISNET Collaborative Breast Cancer Modeling. Medical Decision Making, 2018, 38, 9S-23S.	1.2	37
63	The impact of overdiagnosis on the selection of efficient lung cancer screening strategies. International Journal of Cancer, 2017, 140, 2436-2443.	2.3	36
64	MRS imaging using anatomically based K-space sampling and extrapolation. Magnetic Resonance in Medicine, 1995, 34, 686-693.	1.9	33
65	Prediction of EGFR and KRAS mutation in non-small cell lung cancer using quantitative 18F FDG-PET/CT metrics. Oncotarget, 2017, 8, 52792-52801.	0.8	32
66	Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models. Medical Decision Making, 2018, 38, 3S-8S.	1.2	31
67	Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening. JAMA Oncology, 2021, 7, 1833.	3.4	29
68	Ductal Lavage of Fluid-Yielding and Non-Fluid-Yielding Ducts in BRCA1 and BRCA2 Mutation Carriers and Other Women at High Inherited Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1082-1089.	1.1	27
69	CCAST: A Model-Based Gating Strategy to Isolate Homogeneous Subpopulations in a Heterogeneous Population of Single Cells. PLoS Computational Biology, 2014, 10, e1003664.	1.5	26
70	Estimating Breast Cancer Survival by Molecular Subtype in the Absence of Screening and Adjuvant Treatment. Medical Decision Making, 2018, 38, 32S-43S.	1.2	26
71	Cost-Effectiveness Analysis of Lung Cancer Screening Accounting for the Effect of Indeterminate Findings. JNCI Cancer Spectrum, 2019, 3, pkz035.	1.4	22
72	Comparing the benefits of screening for breast cancer and lung cancer using a novel natural history model. Cancer Causes and Control, 2012, 23, 175-185.	0.8	21

#	Article	IF	Citations
73	Diversity of model approaches for breast cancer screening: a review of model assumptions by The Cancer Intervention and Surveillance Network (CISNET) Breast Cancer Groups. Statistical Methods in Medical Research, 2004, 13, 525-538.	0.7	20
74	p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia. Oncotarget, 2015, 6, 3563-3577.	0.8	20
75	Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage. Health Expectations, 2005, 8, 221-233.	1.1	18
76	Bridging Population and Tissue Scale Tumor Dynamics: A New Paradigm for Understanding Differences in Tumor Growth and Metastatic Disease. Cancer Research, 2014, 74, 426-435.	0.4	18
77	Simulation-based parameter estimation for complex models: a breast cancer natural history modelling illustration. Statistical Methods in Medical Research, 2004, 13, 507-524.	0.7	17
78	Digital Storage Phosphor Chest Radiography: An ROC Study of the Effect of 2K versus 4K Matrix Size on Observer Performance. Radiology, 2001, 218, 527-532.	3.6	16
79	Decision Analysis and Simulation Modeling for Evaluating Diagnostic Tests on the Basis of Patient Outcomes. American Journal of Roentgenology, 2005, 185, 581-590.	1.0	16
80	A mathematical algorithm that computes breast cancer sizes and doubling times detected by screening. Mathematical Biosciences, 2001, 171, 155-178.	0.9	14
81	Comparing CISNET Breast Cancer Incidence and Mortality Predictions to Observed Clinical Trial Results of Mammography Screening from Ages 40 to 49. Medical Decision Making, 2018, 38, 140S-150S.	1.2	13
82	Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers. Familial Cancer, 2013, 12, 65-73.	0.9	11
83	Comparing CISNET Breast Cancer Models Using the Maximum Clinical Incidence Reduction Methodology. Medical Decision Making, 2018, 38, 112S-125S.	1.2	11
84	TRAIL-induced variation of cell signaling states provides nonheritable resistance to apoptosis. Life Science Alliance, 2019, 2, e201900554.	1.3	11
85	Simultaneous Class Discovery and Classification of Microarray Data Using Spectral Analysis. Journal of Computational Biology, 2009, 16, 935-944.	0.8	10
86	A Cost-Effectiveness Analysis of Lung Cancer Screening With Low-Dose Computed Tomography and a Diagnostic Biomarker. JNCI Cancer Spectrum, 2021, 5, pkab081.	1.4	10
87	Ethical Issues in Contrast-Enhanced Magnetic Resonance Imaging Screening for Breast Cancer. Topics in Magnetic Resonance Imaging, 2002, 13, 79-84.	0.7	9
88	Reconstructing Directed Signed Gene Regulatory Network From Microarray Data. IEEE Transactions on Biomedical Engineering, 2011, 58, 3518-3521.	2.5	9
89	Precision Medicine in Pancreatic Disease—Knowledge Gaps and Research Opportunities. Pancreas, 2019, 48, 1250-1258.	0.5	9
90	Reflecting on 20 years of breast cancer modeling in CISNET: Recommendations for future cancer systems modeling efforts. PLoS Computational Biology, 2021, 17, e1009020.	1.5	9

#	Article	IF	Citations
91	Multiomics Analysis of Spatially Distinct Stromal Cells Reveals Tumor-Induced O-Glycosylation of the CDK4–pRB Axis in Fibroblasts at the Invasive Tumor Edge. Cancer Research, 2022, 82, 648-664.	0.4	9
92	A Molecular Subtype–Specific Stochastic Simulation Model of US Breast Cancer Incidence, Survival, and Mortality Trends from 1975 to 2010. Medical Decision Making, 2018, 38, 89S-98S.	1.2	8
93	A risk–based framework for assessing real–time lung cancer screening eligibility that incorporates life expectancy and past screening findings. Cancer, 2021, 127, 4432-4446.	2.0	7
94	Modeling the transition of lung cancer from early to advanced stage. Cancer Causes and Control, 2009, 20, 1559-1569.	0.8	6
95	Reducing the Computational Complexity of Information Theoretic Approaches for Reconstructing Gene Regulatory Networks. Journal of Computational Biology, 2010, 17, 169-176.	0.8	6
96	Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition. Molecular Cancer Therapeutics, 2012, 11, 1071-1081.	1.9	6
97	TreeVis: A MATLAB-based tool for tree visualization. Computer Methods and Programs in Biomedicine, 2013, 109, 74-76.	2.6	6
98	Reconstructing codependent cellular cross-talk in lung adenocarcinoma using REMI. Science Advances, 2022, 8, eabi4757.	4.7	6
99	Ductal Pattern Enhancement on Magnetic Resonance Imaging of the Breast Due to Ductal Lavage. Breast Journal, 2007, 13, 281-286.	0.4	5
100	Sparse discriminative latent characteristics for predicting cancer drug sensitivity from genomic features. PLoS Computational Biology, 2019, 15, e1006743.	1.5	4
101	ARF: Connecting senescence and innate immunity for clearance. Aging, 2015, 7, 613-615.	1.4	3
102	Systematic Deconvolution of Hematolymphoid Tumor Transcriptomes Reveals Infiltrating Immune Cell Signatures Related to Survival.. Blood, 2012, 120, 2390-2390.	0.6	3
103	A Bayesian nonparametric method for model evaluation: application to genetic studies. Journal of Nonparametric Statistics, 2009, 21, 379-396.	0.4	2
104	Raising the Bar for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 2014, 161, 532.	2.0	2
105	PS01.77: Risk-Stratification for Second Primary Lung Cancer. Journal of Thoracic Oncology, 2016, 11, S319-S320.	0.5	2
106	Cost-Effectiveness Analysis of Lung Cancer Screening in the United States. Annals of Internal Medicine, 2020, 172, 706-707.	2.0	2
107	Evaluation of Alternative Diagnostic Follow-up Intervals for Lung Reporting and Data System Criteria on the Effectiveness of Lung Cancer Screening. Journal of the American College of Radiology, 2021, 18, 1614-1623.	0.9	2
108	Caution Needed for Analyzing the Risks of Second Cancers. Journal of Thoracic Oncology, 2018, 13, e172-e173.	0.5	1

#	Article	IF	Citations
109	Contributions of Screening and Treatment to Mortality From Breast Cancerâ€"Reply. JAMA - Journal of the American Medical Association, 2018, 319, 2336.	3.8	1
110	Cost-Effectiveness Analysis of New Image-Based Screening Tech;lologies. Computer Aided Surgery, 2000, 5, 134-134.	1.8	0
111	Distinguishing between CISNET model results versus CISNET models. Cancer, 2018, 124, 1083-1084.	2.0	0
112	Re: Think before you leap. International Journal of Cancer, 2018, 142, 1507-1509.	2.3	0
113	Gene Expression Signature of Host Immune Response Is Predictive of Follicular Lymphoma Patient Survival in Independent Cohorts, and Correlates with Transformation to Diffuse Large B-Cell Lymphoma.. Blood, 2009, 114, 2951-2951.	0.6	0
114	Prediction of Survival In Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes Reflecting Tumor and Microenvironment. Blood, 2010, 116, 2006-2006.	0.6	0
115	Identification of LMO2 Transcriptome and Interactome in Diffuse Large B-Cell Lymphoma by Integrated Experimental and Computational Approach. Blood, 2011, 118, 438-438.	0.6	0
116	Abstract A48: Gene expression signatures associated with MYC oncogene addiction in lymphoma. , 2015, , .		0